Autism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Autism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 6, 26, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

4D Pharma Plc
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Allos Pharma Inc
AsiaBiome
Axial Therapeutics Inc
Cennerv Pharma (S) Pte Ltd
ChunLab Inc
Cognosetta Inc
Curemark LLC
Enterin Inc
Epigen Biosciences Inc
EuMentis Therapeutics Inc
Herophilus
Hopstem Biotechnology LLC
iCELL Biotechnology Co Ltd
ImmunoBiome Inc
Immuron Ltd
Intra-Cellular Therapies Inc
Intrinsic Medicine Inc
Johnson & Johnson
Kuzani Pharmaceuticals Inc
MD Healthcare Inc
Omeros Corp
OptiNose Inc
Oryzon Genomics SA
Palisades Therapeutics
Panorama Researchama Research
Park Active Molecules
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
RogCon Inc
Rugen Therapeutics R&D (Shanghai) Co Ltd
Scioto Biosciences Inc
SciSparc Ltd
Sengenics Corp Pte Ltd
Standigm Inc
Stem Cell Medicine Ltd
Sumitomo Dainippon Pharma Co Ltd
Tempero Bio
The Greater Cannabis Company Inc
Vanda Pharmaceuticals Inc
Yamo Pharmaceuticals LLC
Zelira Therapeutics Ltd